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In  this work,  a  highly  sensitive  label-free  immunosensor  for detection  of  the  main biomarker  of
Alzheimer’s  disease  (AD), amyloid  beta  1–42  (A  (1–42)),  is  presented.  A gold  electrode  was  modified
with  a mercaptopropionic  acid  (MPA)  self-assembled  monolayer,  electrodeposited  gold  nanoparticles
(AuNPs)  and  a monoclonal  antibody  mAb  DE2B4  to recognize  A;  all  the  relevant  experimental  variables
were  optimized.  Antibodies  were  functionalized  through  chemical  modification  (thiolation)  to  promote
the  antibody  immobilization  on  the  AuNPs  surface  with  proper  orientation  which enabled  the  direct
detection  of  A(1–42).  Scanning  electron  microscopy,  square-wave  voltammetry  and electrochemical
impedance  spectroscopy  were used  to  characterize  the  construction  of  the biosensor.  Using  the pro-
−1posed  immunosensor,  A(1–42)  was  specifically  detected  within  the linear range  of 10–1000  pg  mL
with a 5.2  pg  mL−1 and  17.4 pg  mL−1 detection  and  quantification  limit,  respectively;  recovery  values  for
the  tested  spiking  levels  ranged from  90.3  to 93.6%.  The  immunosensor  enables  rapid,  accurate,  precise,
reproducible  and  highly  sensitive  detection  (14.6%reduction mL pg−1)  of A  with  low-cost  and  opens  the
possibilities for  diagnostic  ex  vivo applications  and  research-based  in  vivo  studies.
      .. Introduction
Alzheimer’s disease (AD) is a neurodegenerative pathology
hat becomes increasingly common with aging, characterized by
xtracellular accumulation of amyloid  peptide (A), intracellu-
ar appearance of neurofibrillary tangles and neuronal loss [1,2].
his degeneration leads to changes in behavior, personality and
unctional capacity, which hampers the daily life of the patient.
owadays it affects 35 million individuals worldwide and it is esti-
ated to affect 115 million people by 2050 [3].
The  current diagnostic procedures of AD are difficult and made
n an advanced stage of the disease. In addition, there are no treat-
ents available that prevent this condition. Therefore, there is a
ontinuing demand for fast and simple analytical methods for the
etermination of many clinical and biochemical parameters [4–6].Research gives support to the “amyloid cascade hypothesis”,
hich advocates that an imbalance between the production and
learance or degradation of A in the brain is the initiating event
∗ Corresponding author.
E-mail address: sbm@isep.ipp.pt (S. Morais).in AD, leading to the formation of extracellular deposits of A
(senile plaques) [7]. The peptide with 42 amino acids, A(1–42),
is the major component of the senile plaques found in AD. Other
pathological hallmarks of AD include intraneuronal inclusions
of hyperphosphorylated tau protein in neurofibrillary tangles,
together with downstream processes such as inflammation and
oxidative stress. All of these steps contribute to the loss of synap-
tic integrity, effective neural network connectivity and progressive
neurodegeneration [3,5,8,9].
A(1–42) can be expressed in cerebrospinal fluid (CSF) and
plasma. More specifically, CSF levels of A(1–42) are lower in AD
patients than in normal controls, reflecting amyloid pathology.
Specifically, low CSF A(1–42) levels are detected in preclinical
disease stages and predict future cognitive decline and neu-
rodegeneration [10]. An A(1–42) concentration of < 500 pg mL−1
(0.1 nM)  is indicative that A(1–42) is accumulating in the brain
and not circulating in the CSF [10].
Currently, most of the A(1–42) assays rely on immunochemical
detection  such as the conventional enzyme linked immunoassay
(ELISA) [10,11] which are methods that present high sensitivity,
good specificity and less dependence on sample preparation [12].
Recently, an ELISA assay was  optimized and validated present-
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9ng a detection limit of 375 pg/mL [11]. In this work we present
n electrochemical immunosensor which is particularly attractive
n the field of diagnosis because biosensors unite the specificity
nd affinity of the antibody-antigen reaction with the inherent
haracteristics of electrochemical techniques such as high sensi-
ivity, low cost, high efficiency and easy miniaturization [13–16].
 critical aspect in the development of an immunosensor is the
ntibody immobilization. The chosen method should be capable of
mmobilizing a high density of antibodies, maintaining the antibod-
es bioactivity and promoting the antibodies immobilization with
roper orientation to interact favorably with its target antigens
12,17]. Nowadays mouse monoclonal antibody (mAb) are being
sed for targeting drugs, proteins and peptides to the brain as they
re able to recognize a specific antigen [18,19]. In this work, the
ntibody used was the DE2B4 that is able to recognize the A(1–42),
nce this anti-beta amyloid antibody bind at the region of 1–17
mino acid. The specificity of this mAb  was previously studied
20–22].
Self-assembled monolayers (SAMs) have been used for years in
lectroanalytical chemistry as the basis for sensors, as they are
 simple technique to modify and control the interface of cer-
ain materials allowing the immobilization of biomolecules, as for
xample, antibodies [23,24]. However, the available surface area
or the binding of antibody with retention of their bioactivity is
till a major issue [17]. For overcoming this problem, SAMs can
e coupled with nanoscale materials, which present unique phys-
cal properties, ideal for the development of a sensing platform
17,25]. Gold nanoparticles (AuNPs) are chemically stable, non-
oxic and easy to functionalize [26,27]. From an electroanalytical
oint of view, AuNPs are particularly interesting because of their
igh stability, good biological compatibility, excellent conducting
apability and high surface-to-volume ratio [26,28,29]. Moreover,
he use of AuNPs should not only enable the immobilization of a
igher amount of antibody but also preserve the activity of the
mmobilized biomolecules, thus offering higher sensitivity and
electivity than conventional strategies. These features provide
xcellent prospects for interfacing biological recognition events
ith electronic signal transduction and make AuNPs extremely
uitable for developing novel and improved electrochemical sens-
ng and biosensing systems [29–31].
In this work, we present a simple and sensitive gold label
ree immunosensor for the quantification of AD main biomarker,
(1–42), with the goal of performing a clinical diagnosis and
onitor biochemical effects of AD treatments. The sensor’s plat-
orm was composed of AuNPs which were electrodeposited on
he previously mercaptopropionic acid (MPA) modified gold elec-
rode (MPA/Au electrode). Then, the antibody mAb  DE2B4 against
(1–42) was functionalized through chemical modification (thi-
lation) to promote the antibody immobilization on the AuNPs
urface with proper orientation which enabled the direct detection
f A(1–42). Square-wave voltammetry (SWV) and electrochem-
cal impedance spectroscopy (EIS) were used to characterize the
onstruction of the biosensor and assess the immune reaction
etween the modified electrode and A(1–42).
. Material and methods
.1. Materials
Mouse monoclonal antibody DE2B4 (1 mg  mL−1) IgG (ab11132)
as purchased from Abcam (UK). Human antigen -amyloid
eptide (1–42), purity >95%, was purchased from Genscript (USA).
oat anti-mouse IgG secondary antibody was purchased from
ierce antibodies/Thermo Scientific (USA). Sulfuric acid (H2SO4,
8%), hydrogen peroxide (H2O2, 30%), N-hydroxysuccinimide(NHS), citric acid, sodium citrate dihydrate, gold(III) chloride solu-
tion, ethylenediaminetetraacetic acid (EDTA), 2-imninothiolane
hydrochloride, citrate buffer solution, albumin form bovine
serum (BSA) N-(3, Dimethylaminopropyl)-N-ethyl-carbodiimide
hydrochloride (EDC), 2,2′-Azino-bis(3-ethylbenzothiazoline-
6-sulfonic acid) diammonium salt (ABTS), cystamine and
potassium ferrocyanide (K4[Fe(CN)6]·3H2O), potassium ferri-
cyanide (K3Fe(CN)6), potassium hydrogen phosphate (K2HPO4)
and potassium dihydrogen phosphate (KH2PO4) were purchased
form Sigma-Aldrich (Steinheim, Germany). 2-mercaptoethanol,
3-mercaptopropionic acid solution and glutaraldehyde were pur-
chased from Fluka (Switzerland). Absolute ethanol was obtained
from Panreac (Spain). Potassium nitrate (KNO3) was purchased
from Pronalab (Mexico). Milk powder was  obtained from Molico
Nestlé. Alumina solution (-Al2O3) 0.3 m and 0.05 m were
purchased from Gravimeta. Ultrapure water (18.2 Mcm−1 resis-
tivity)  was  produced by a Milli-Q Simplicity 185 system (Millipore,
Molsheim, France).
2.2. Electrochemical measurements
Electrochemical experiments were performed with a  poten-
tiostat/galvanostat, AUTOLAB model PGSTAT 30 (Metrohm-Eco
Chemie, The Netherlands) controlled by a computer through the
Model NOVA version 1.9 software. A conventional three-electrode
cell was used for all electrochemical measurements: the devel-
oped biosensor (based on a polycrystalline gold electrode, BASi
MF-2014, surface area 2.0 mm2 and diameter of 1.6 mm)  as a work-
ing electrode, platinum as counter-electrode and a Ag|AgCl|3 M
KClsat reference electrode to which all potentials are referred.
Square-wave voltammetry (SWV) and electrochemical
impedance  spectroscopy (EIS) were performed using Fe(CN)63−/4−
as electroactive indicator at a concentration of 2.5 mM  in 0.1 M
PBS solution (pH = 7.4). SWV  results were obtained by varying the
potential from 0.00 to 0.60 V at 0.400 V/s scan rate. The optimal
SWV parameters were a frequency of 100 Hz, amplitude of 40 mV
and scan increment of 4 mV.  EIS measurements were performed
using a frequency range from 10−1 to  105 Hz with an amplitude
perturbation of 5 mV.
2.3. Immunosensor development
The surface of the bare gold electrode was  cleaned using piranha
solution (30:70, v/v, H2O2 and H2SO4) at room temperature (RT) for
5 min. Then the electrode was  polished repeatedly with 0.3 and
0.05 m alumina powder on microfiber cloth. Subsequently the
surface was  rinsed with ultrapure water and ultrasonically cleaned
in absolute ethanol. After that, the electrode was cycled from 0.0 to
1.6 V in 0.5 M H2SO4 solution  at a scan rate of 100 mV/s. The pro-
cess was  repeated until typical gold cyclic voltammograms were
obtained. Finally, the electrode was  washed with ultrapure water
and modified (Fig. 1).
2.3.1. Self-assembled monolayer
Four  different SAMs were studied by immersing the gold elec-
trode, for a 12 h period at RT, in ethanol solutions of cystamine
(CYS) (20 mM),  cystamine + mercaptoethanol (CYS + ME)  (20 mM),
mercaptopropionic acid (MPA) (1 mM)  and mercaptopropionic
acid + mercaptoethanol (MPA + ME)  (1 mM).  After washing with
ultrapure water, the CYS modified electrodes were immersed for
a period of 30 min  in a 3% glutaraldehyde solution, while the other
modified (MPA) electrodes were immersed in an EDC/NHS solution.
After selection of the optimum SAM, the incubation time
(2–12 h) and concentration of the solution (1–20 mM)  for the SAM
formation were optimized.
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In brief, the final process consisted in immersing the previ-
usly cleaned gold electrode for 2 h at room temperature in an
thanol solution of mercaptopropionic acid (5 mM).  After washing
ith ultrapure water, a solution of EDC/NHS was  dropped on the
odified gold electrode surface for 30 min.
.3.2. Gold nanoparticles electrodeposition
To immobilize AuNPs on the electrode surface, the modified
MPA/Au) electrode was immersed in 0.1 M KNO3 solution contain-
ng 3 mM HAuCl4 while a − 200 mV  working potential was applied
o the electrode [32]. In order to optimize AuNPs immobilization,
hree electrodeposition periods were tested: 100, 150 and 200 s.
.3.3. Antibody immobilization
Antibodies  against A(1–42) were immobilized on the AuNPs
urface using thiol(-SH) groups. The antibodies were prepared
hrough chemical modification (thiolation) with EDTA and Trautı´s
eagent. A mixed solution containing 1 L of EDTA (0.28 M),  82.6 L
f iminothiolane (0.006 mM)  and monoclonal antibody against
(1–42) was prepared after dilution with PBS (0.1 M,  pH 7.4).
he prepared solution reacted for 50 min  at room temperature.
fter reacting, the solution was completed with PBS in order to
ake up a volume of 500 L. This solution was purified through
 sephadex PD MiniTrap G-25 column (GE Healthcare), following
he gravity protocol. To immobilize the antibody against A(1–42),
he AuNPs/MPA/Au electrode was immersed in the antibody solu-
ion (1.0, 2.0 or 5.0 g mL−1) followed by incubation at 4 ◦C  during
ve different tested periods (2, 5, 7, 10 or 12 h). At last, the anti-immunosensor development.
A(1–42)/AuNPs/MPA/Au electrode was immersed in a 10 g mL−1
BSA solution for 5 min  at 4 ◦C  in order to block the remaining
adsorption-reactive sites (Fig. 1).
2.4. ELISA
The functional activity of the antibodies was analyzed by
the enzyme-linked immunosorbent assay (ELISA). The surface of
96 well plates (flat-bottom Nunc MaxiSorp®) was  coated with
A(1–42) during 1 h at 37 ◦C.  After blocking with non fat dry milk
10%, the primary antibody was  added to each well. After a wash-
ing step, the secondary antibody conjugated with peroxidase (Goat
anti-Mouse IgG (H + L) Cross Adsorbed Secondary Antibody, HRP
conjugate, Thermo Scientific-Pierce Antibodies) was allowed to
react for 45 min  at RT. To reveal the presence of the antibodies in the
wells, a citrate solution was  used with citric acid, ABTS (2,2′-azino-
bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt) and
H2O2. The intensity of the color was  measured by spectrophotom-
etry using a Biotek Synergy 2 spectrometer. Wells without primary
antibody were used as control.
2.5. Electrochemical detection of Aˇ(1–42)The BSA/anti-A(1–42)/AuNPs/MPA/Au electrode was
immersed in a PBS solution at pH 7.4 containing a concentra-
tion of A(1–42) in the range of 10–1000 pg mL−1 at  RT for 10 min.
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Mll measurements were carried out in triplicate. The current
eduction (% IR):
IR = [1−(Ip/Ip◦)]  × 100 (1)
here Ip◦ and  Ip are the peak currents of Fe(CN)63−/4− (used as
lectroactive indicator at a concentration of 2.5 mM in 0.1 M PBS
olution, pH = 7.4) before and after the incubation with A(1–42),
espectively, was employed to obtain A(1–42) analytical curves.
hen the electrode was thoroughly rinsed with PBS and ultrapure
ater to remove unbound antigen, and stored at 4 ◦C.
.6. Scanning electron microscopy
Scanning electron microscopy (SEM; FEI Quanta 400FEG
SEM/EDAX Genesis X4 M)  was used to observe the morphological
roperties of the developed biosensor.
. Results and discussion
.1. Immunosensor development.1.1. Self-assembled monolayer formation
The different steps involved in the preparation of the
mmunosensor are schematically illustrated in Fig. 1. The first opti-
ized step concerned the modification of the gold electrode with
ig. 2. Influence of the tested self-assembled monolayer (SAM) in the current
eak  reduction using Fe(CN)63−/4− as  electroactive indicator at a concentration
f  2.5 mM in 0.1 M PBS solution (pH = 7.4). CYS: cystamine (20 mM), CYS + ME:
ystamine  + mercaptoethanol (20 mM),  MPA: mercaptopropionic acid (1 mM), and
PA + ME: mercaptopropionic acid + mercaptoethanol (1 mM).
Fig. 3. SEM images of (a) bare gold electrothe several tested SAMs (CYS (20 mM),  CYS + ME  (20 mM), MPA
(1 mM)  and MPA  + ME  (1 mM)). They formed an organic assembly
on the electrode surface that led to a block in the electron transfer
between the surface of the electrode and the Fe(CN)63−/4− solution
which consequently caused a signal reduction in the peak current.
The SAM that best adsorbed to the electrode surface was composed
of MPA  (ca. 87% of peak reduction) and was the selected SAM to form
the basis of the developed immunosensor (Fig. 2). Subsequently, the
influence of incubation time (2–12 h) and concentration (1–20 mM)
was characterized. After the first 2 h of incubation, only a 1%
reduction in the peak current was observed every 2 h, thus it was
concluded that a period of 2 h is sufficient to form a stable, orga-
nized and packed layer on the gold electrode surface. Regarding the
concentration, the peak current decreased with increasing of MPA
concentrations till ca. 5 mM and higher values led to a stabilization
of the peak current, which implied that the electrode surface has
been entirely covered with MPA. Thus, 5 mM was  considered the
most favorable concentration of MPA. The optimized conditions are
in accordance with the values found in literature as periods of incu-
bation ranging from 30 min–12 h and MPA  concentrations ranging
from 0.1–10 mM were found [12,33–38].
3.1.2. Gold nanoparticles electrodeposition
The deposition of AuNPs on the modified gold electrode
(MPA/Au electrode) reduced the charge transfer resistance and,
consequently, a large increase in the peak current was observed.
In order to optimize the deposition of AuNPs on the modified elec-
trode surface, three different periods (100, 150 and 200 s) were
investigated based on the electroactive indicator peak current using
square-wave voltammetry; no significant difference between them
was detected since it was  possible to recover about 97% of the orig-
inal gold signal (before SAM immobilization) in the three cases.
Therefore, a period of 100 s was chosen for the subsequent assays;
this electrodeposition period is about three times less than the
one presented by Park et al. ([32]). The successful deposition of
the AuNPs on MPA/Au electrode was  confirmed by SEM (Fig. 3)
that showed a rough surface and AuNPs uniformly and densely
distributed. These are both indicators of the strong interaction
between the AuNPs and the MPA  layer.
3.1.3. Antibody immobilization
The  antibodies were functionalized through chemical modifi-
cation (thiolation). The aim of this treatment was to immobilize
the antibodies on the AuNPs surface with the proper orientation,
by using thiol groups, in order to make the antigen binding site
available. For this purpose the antibody was treated with Traut’s
reagent and EDTA. The reagent reacted with the amine groups in the
de and (b) AuNPs/MPA/Au electrode.
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eig. 4. Nyquist plots of the different stages of the immunosensor development
(1–42)/AuNPs/MPA/Au electrode; e) BSA/anti-A(1–42)/AuNPs/MPA/Au electro
erformed in 2.5 mM Fe(CN)63−/4− solution  in 0.1 M PBS (pH = 7.4) applying a freque
ntibodies to result in permanent modifications containing termi-
al sulfhydryl residues [39]. EDTA was required to stop completely
etal-catalyzed oxidation of sulfhydryl groups [39]. To immobilize
he antibody against A(1–42) on the AuNPs/MPA/Au electrode,
everal concentrations of antibody solution (1.0, 2.0 or 5.0 g mL−1)
nd incubation times (2–12 h) were tested. The antibody immobi-
ization caused a large signal reduction of the Fe(CN)63−/4− redox
ouple due to the formation of a protein layer that partially blocked
he AuNPs/MPA/Au electrode surface, making the electron transfer
rocess between the electrode and the solution slower and more
ifficult. The signal reduction was proportional to the increase of
nti-A(1–42) concentration and incubation time. The optimum
onditions were found to be a 2.0 g mL−1 antibody concentration
nd an incubation time of 2 h.
.1.4. Electrochemical characterization of the immunosensor
In  order to characterize the fabrication process of the
mmunosensor, EIS and SWV  were recorded at each step and are
resented in Figs. 4 and 5, respectively. EIS is one of the most
owerful electroanalytical techniques frequently used in charac-
erizing materials and surface interfaces [17,32,40]. The advantage
f EIS over other electrochemical techniques is that it requires
nly a small amplitude perturbation from the steady state, which
akes it possible to analyze responses theoretically by linearized
r otherwise simplified current-potential characteristics [40]. The
mpedance spectra include a semicircle portion and linear por-
ion, which can be used to describe the interface properties of
he electrode for each immobilized step. The semicircle diameter
t higher frequencies corresponds to the electron-transfer resis-
ance, which controls the electron transfer kinetics of the redox
rocess at the electrode interface. At lower frequencies, the linear
art is typical of a mass diffusion-limited electron-transfer pro-
ess [41,42]. A significant change in the impedance spectra can be
bserved after each modification of the gold electrode with MPA,
uNPs, anti-A(1–42), BSA and A(1–42) in comparison with the
are gold electrode which exhibited a typical pattern of mass diffu-
ion limited process (Fig. 4). The SAM of MPA  formed an organized
nd packed layer that blocked the surface of the gold electrode
ncreasing the charge-transfer resistance and consequently a semi-
ircle in the impedance spectra was observed. Then AuNPs were
lectrodeposited onto the MPA/Au electrode and the electron trans-are gold electrode; b) MPA/Au electrode; c) AuNPs/MPA/Au electrode; d) anti-
d f) A(1–42)/BSA/anti-A(1–42)/AuNPs/MPA/Au electrode. Measurements were
ange from 10−1 to  105 Hz  with an amplitude perturbation of 5 mV.
fer resistance significantly decreased, reducing significantly the
diameter of the semicircle. AuNPs present high conductivity that
improves the electron transfer rate. In contrast after the immobi-
lization of anti-A(1–42) and BSA, the diameters of the semicircle
were significantly enlarged due to the generation of an insulating
protein layer on the modified electrode surface which hindered the
electron transfer. These results also proved that the anti-A(1–42)
and BSA were successfully immobilized on the modified electrode
surface. AuNPs are widely used nanomaterials because of their large
specific surface area, strong adsorption ability, and high conduc-
tivity. They can strongly interact with biomaterials and they have
been used as a mediator to immobilize biomolecules and to effi-
ciently retain their activity [26,28,29]. This pattern of variation is
consistent with the results attained by SWV  (Fig. 5).
3.2. Electroanalytical performance of the immunosensor
The ability of the antibodies of recognizing their ligands was
assessed by ELISA. Firstly, the antigen A(1–42) was  adsorbed to
the bottom surface of a 96 well plate and then it was incubated
with the mAb  DE2B4 (or with buffer for control); finally, to assess
the formation of the antigen-antibody binding, a secondary anti-
body was used revealing the presence or absence of A(1–42). As a
result of this test, it was  concluded that a 5 min  period was enough
to promote the link between the antigen and the antibody. Still, in
order to ensure that maximum sensitivity for detection of A(1–42)
was attained, 10 min  of incubation was  subsequently applied. For
this incubation time in the wells previously coated with amyloid
beta, the control (buffer) used in the assays exhibited significantly
lower absorbance at 405 nm (0.078 ± 0.003) when compared to
the antibody (0.23 ± 0.03), suggesting a sufficient antibody-antigen
reaction time.
Under  the optimal conditions, the peak current reduction
(%) observed when the biosensor was exposed to different con-
centrations of A(1–42) (10 − 1000 pg mL−1) was  recorded.
Representative  voltammograms are exhibited in Fig. 6a. In the
presence of A(1–42), the peak potential shifted positively due
to alteration of the interface properties of the biosensor sur-
face (that affected the electron transport) promoted by the
capture of A(1–42) by the mouse monoclonal antibody (anti-
A(1–42)). The analytical curve (Fig. 6b), i (%) = 14.60
(
%mLpg
)
×
Fig. 5. Square-wave voltammograms for the different stages of the immunosensor development: a) bare gold electrode; b) MPA/Au electrode; c) AuNPs/MPA/Au electrode;
d)  anti-A(1–42)/AuNPs/MPA/Au electrode; e) BSA/anti-A(1–42)/AuNPs/MPA/Au electrode. Measurements were performed in 2.5 mM Fe(CN)63−/4− solution  in 0.1 M PBS
(pH  = 7.4).
Fig. 6. a) Square-wave voltammetric response of the immunosensor to different concentrations of A(1–42) (from a to f: 0, 10, 50, 100, 500 and 1000 pg mL−1).  Measurements
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rere performed in 2.5 mM Fe(CN)63−/4− solution  in 0.1 M PBS (pH = 7.4); b) Calibrat
og Diff 6
[
A (1  − 42)pgmL−1
]
− 11.50 (%) ,  presented good sensi-
ivity  (14.6%reduction mL  pg−1), wide linearity and good distribution
f the data, even at low levels, with a correlation coefficient (r) of
.982. The detection (LOD) and quantification (LOQ) limits were
alculated, using the standard deviation of the intercepts and the
verage of slopes of the straight lines from the analytical curves,
o be 5.2 pg mL−1 (1.1  pmol L−1) and 17.4 pg mL−1 (3.85  pmol L−1),
espectively. The attained LOD, combined with the simplicity of
he proposed immunosensor and fast response, compares favorably
ith the previously reported ones for the detection of A(1–42)
Table 1) [10,43–54]. Out the fourteen sensors for A (1–42) detec-
ion presented in Table 1, only three [47–49] have a LOD in the
ame range as the one reached in this work but involving longer
nd much more complex schemes. The detection of A(1–42) is
erformed in just 10 min  which is significantly lower than the
eported periods (≥30 min  [55]). Moreover, due to its simplicityrve based on the current reduction observed.
and short analysis time this method allows real time monitoring
and with its label-free detection it obviates the need of expensive
biotin or enzyme-linked antibody and functionalized nanoparti-
cles for recognition and signal amplification, reducing the operation
complexity and assay cost.
Additionally,  the intra-repeatability was estimated at a con-
trolled A(1–42) concentration of 0.30 ng mL−1. Intra–day (n = 6)
exhibited relative standard deviations (RSD) of 4.0. The repro-
ducibility of immunosensor was also assessed using three different
modified electrodes and the attained RSD was  2.4%. The long-time
stability of the immunosensor was  evaluated. The current response
of the prepared immunosensor decreased 18% after five days stor-
age in PBS (pH = 7.4) at 4 ◦C  thus presenting acceptable stability.
Overall, the proposed procedures exhibit appropriate features for
analytical purposes.
The  accuracy and applicability of the proposed biosensor
was tested by recovery assays performed at two spiking levels.
Table  1
Review of reported immunosensors for A(1–42) detection.
Transducer Immobilization Analyte Detection LOD (pg mL−1)  Ref.
Silicon/Silicon oxide Poly(DMA-co-NAS-co-MAPS)* A(1–42) Circular dichroism spectroscopy 73 [10]
Silicon wafer Functionalization of the substrate
with carboxylated
alkyltrichlorosilane
A(1–42) X-ray Photoemissive Spectroscopy
and  Fluorescent microscopy
3.0 × 105 [43]
Carbon electrode AuNPs/SAM formation of the
acetylenyl group/cycloaddition
reaction  of an azide-terminated
sialic  acid
A(1–40) and A(1–42) Differential Pulse Voltammetry 4.5 × 106# [44]
Gold electrode Peptide probe
(11-mercaptoundecanoic
acid  + Peptide chain + Ferrocene)/9-
mercapto-1-nonanol
A(1–42) soluble oligomer Square-Wave Voltammetry 1.1 × 103# [45]
Glassy carbon
electrode
Direct immobilization on the
electrode surface
A (1–40) and A(1–42) Square-Wave Voltammetry 7.0 × 105 [46]
CNT film-based
biosensor with a metal
semiconductor  field
effect  transistor
structure
Au with protein G or auto
displayed Z-domains of protein-A
A(1–42) Study of conductance 1 [47]
Gold screen printed
electrode
POPA co-polymer**/Biotinylated
cellular prion protein
(PrPc-residues95–110)
A(1–42) oligomers Electrochemical Impedance
Spectroscopy
2.3## [48]
Anodic aluminium
oxide  substrate (AAO)
Thin gold film sputtered onto the
AAO/AuNPs/11-
mercaptoundecanoic acid
SAM
A(1–42) Electrochemical Impedance
Spectroscopy
1 [49]
Glassy carbon
electrode
Bio-conjugate of horseradish
peroxidase(HRP)-AuNPs–gelsolin
Soluble
A(1–40)/A(1–42)
Differential Pulse Voltammetry 126## [50]
Gold electrode Alkalinephospahte-cystein-
Prp(95–115)peptide
A oligomers Cyclic voltammetry 13.5# [51]
Screen-printed carbon
electrodes
AuNPs/Streptavidin/Biotin-A
(1–42)
A(1–42) Cyclic voltammetry 100 [52]
Gold electrode mercaptopropionic acid
SAM/Antibody/Streptavidin-
conjugated alkaline phosphatase
and  biotinylated A peptides
A(1–42) and total A Amperometric detection 22.6## [53]
Carbon disposable
electrochemical
printed chip
SAM-AuNPs A(1–42) Electrochemical impedance
spectroscopy
2.6 × 103## [54]
Gold electrode MPA  SAM/AuNPs/Anti- A(1–42) −
(EDTA+ Traut’s reagent)
A(1–42) Square-Wave Voltammetry 5.2 This work
*Ter-copolymer made from dimethylacrylamide (DMA),3-(trimethoxysilyl)propylmethacrylate(MAPS) and N-Acryloyloxysuccinimide(NAS).
**Co-polymer of polytyr- amine/3-(4-hydroxyphenyl) propionic acid.
#Value was  expressed in mol  L−1 and  converted to pg mL−1 .
##Value was expressed in pM and converted to pg mL.
Table 2
Recovery assays (n = 4) of the proposed immunosensor.
Sample Standard value
(pg  mL−1)
Found  (pg mL−1)  Recovery (%) Relative standard
deviation (%)
R
t
d
i
w
b
m
t
i
e
t
s
n
q
d
t1 30 27.1 90.3 24.7
2  300 280.9 93.6 3.5
ecoveries of 90.3% and 93.6% were reached at the fortifica-
ion concentration of 30 and 300 pg mL−1, respectively (Table 2),
emonstrating the good accuracy and precision of the developed
mmunosensor. Still, a relatively high standard deviation (24.7%)
as obtained at the lowest spiking level which may  be explained
y the increase of variability observed during analytical measure-
ents (independently of the applied technique) when levels near
he LOQ are quantified. Thus, the label-free methodology presented
n this work proves to be simpler, faster and cheaper than other
lectrochemical biosensors while maintaining appropriate elec-
roanalytical performance. However, it can be expected that the
elected mouse monoclonal antibody may  be also able to recog-
ize A(1–40). Nowadays, substantial evidence indicates that the
uantity of A in different pools, may  be more closely related to
isease state. Due to this new relevant discover, it is also important
o determine the total amount of A (between 38 and 43 aminoacids). Still, A(1–42) is the main biomarker of Alzheimer’s disease
and the more cytotoxic [3]. This peptide is the major component
of the senile plaques found in Alzheimer’s disease; A(1–42) is
the most fibrillogenic sequence and is thus associated with dis-
ease states. An A(1–42) concentration of < 500 pg mL−1 (0.1  nM)
in cerebral spinal fluid is indicative that A(1–42) is accumulat-
ing in the brain [10]. Biosensors for A detection are scarce and
even scarcer those that tested different A peptides [55,56]. In that
regards, it is worth to mention the work that has been performed
by Liu et al. [53,56]. This research team developed two sensitive and
selective electrochemical immunosensors for determining the total
concentration of A(1–40/1–42) and the relative level of A(1–42)
by signal amplification of A(1–16)-heme-modified gold nanopar-
ticles (AuNPs) (A(1–16)-heme-AuNPs) and p-aminophenol (p-AP)
redox cycling, respectively [53–56].
4. Conclusions
A simple and rapid label-free electrochemical immunosensor
based on a modified gold electrode for the detection of A(1–42)
was developed. The structure of the presented immunosensor
exhibits several advantages. The MPA  self-assembled monolayer
formed a stable, organized and packed layer on the surface of
t
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[
[he gold electrode which enabled a fast and successful elec-
rodeposition of AuNPs. Due to their excellent conductive and
atalytic properties, AuNPs acted as an “electronic wire” and pro-
oted the communication between the mediator and the electrode
urface, and amplified the electrochemical reactions. The pro-
osed immunosensor showed a low detection limit, wide linear
ange, good accuracy and reproducibility. Furthermore, the pro-
osed biosensor offers interesting possibilities for detection of the
elected biomarker since it uses simple and relatively inexpensive
nstrumentation. Its application is intended to be cheaper, easier
nd faster than conventional methodologies. It can constitute a
ovel approach to monitor biochemical effects of AD treatments,
nd to facilitate the clinical diagnostic because biomarker levels are
ignificantly related with stage of AD. However, it can be expected
hat the selected mouse monoclonal antibody may  be also able
o recognize A(1–40) which may  be a limitation of this study.
ince data attained with real biological samples (plasma and cere-
ral spinal fluid) are precious, more comprehensive studies will be
onducted in the near future.
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